Sold as Proventil, Ventolin. Every FDA application for this active ingredient: 2 branded and 4 generic.
As of Nov 15, 2026, FDA lists 6 applications for Albuterol (sold as Proventil, Ventolin), first approved May 1, 1981, with 3 new uses approved and 0 published complete response letters.
| Albuterol Sulfate HFA | Part D | $521M | -6% | 7,260,387 |
| Ventolin HFA | Part D | $114M | -26% | 614,886 |
| Albuterol Sulfate | Part D | $9.4M | -5% | 120,717 |
| Albuterol Sulfate (J7613) | Part B | $7.3M | +32% | 220,085 |
| Proair Respiclick | Part D | $3.6M | -21% | 27,083 |
| Albuterol Sulfate (J7611) | Part B | $61K | +16% | 6,588 |
| Albuterol Sulfate (J7612) | Part B | $52K | +9% | 735 |
| Proair Digihaler | Part D | $11K | -97% | 109 |
| Proair HFA | Part D | $0K | -100% | 0 |
| Proventil HFA | Part D | $0K | -100% | 0 |
| Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationParoxysmal Atrial Fibrillation · China National Center for Cardiovascular Diseases | Not applicable | Recruiting | Oct 16, 2026 |
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)COPD Exacerbation · University of Tennessee Graduate School of Medicine | Phase 4 | Not yet recruiting | Jul 23, 2026 |
| Clearance in Primary Ciliary DyskinesiaPrimary Ciliary Dyskinesia, PCD · University of North Carolina, Chapel Hill | Not applicable | Not yet recruiting | Jul 13, 2026 |
| Fasenra: An Asthma StudyEosinophilic Asthma, Severe Asthma · Endeavor Health | Phase 4 | Enrolling by invitation | Jun 17, 2026 |
| The Role Intraoperative Salbutamol Inhaler in Preventing AtelectasisAtelectases, Postoperative Pulmonary, Diabete Mellitus · King Abdullah University Hospital | Early phase 1 | Not yet recruiting | May 15, 2026 |
| Bilevel Positive Airway Pressure (BPAP) for Severe AsthmaPediatric Asthma, Acute Asthma · Columbia University | Not applicable | Not yet recruiting | May 12, 2026 |
| Ventilation and Perfusion in AsthmaticsAsthma · University of Miami | Phase 4 | Recruiting | Feb 23, 2026 |
| Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric SurgeryBariatric Surgery · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | Not applicable | Not yet recruiting | Jan 30, 2026 |
| May 1, 1981 | ProventilNDA 17559 · New molecular entity | Schering | 20 | Discontinued |
| May 1, 1981 | VentolinNDA 18473 · New formulation or manufacturer | Glaxosmithkline | 23 | Discontinued |
| Dec 28, 1995 | AlbuterolANDA 73272 | Ivax Sub Teva Pharms | 10 | Discontinued |
| Aug 1, 1996 | AlbuterolANDA 74072 | Pliva | 9 | Discontinued |
| Aug 14, 1996 | AlbuterolANDA 72273 | Armstrong Pharms | 14 | Discontinued |
| Aug 19, 1997 | AlbuterolANDA 73045 | Genpharm | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Schering
Glaxosmithkline